Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder

International Clinical Psychopharmacology

Volumn 26, Issue 3, 2011, Pages 173-180

  Liu, Xianchen ^a,b   Tepper, Ping G ^c   Able, Stephen L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

duloxetine; duration of therapy; healthcare utilization; major depressive disorder; medication adherence

Indexed keywords

DULOXETINE;

ADULT; ARTICLE; COMORBIDITY; DEMOGRAPHY; EMERGENCY WARD; FEMALE; FOLLOW UP; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; HOSPITALIZATION; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; THIOPHENES; TIME FACTORS; YOUNG ADULT;

EID: 79954896006     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328343ba1e     Document Type: Article

References (29)

1. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC (2006). Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 44:300-303. (Pubitemid 43755432)
2. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. (Pubitemid 17055592)
3. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM (2008). The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 62:76-87. (Pubitemid 350294021)
4. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002a). Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315. (Pubitemid 34456358)
5. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA (2002b). Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36:383-390. (Pubitemid 35254112)
6. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychophar-macol 14:457-470. (Pubitemid 39626894)
7. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (2002). Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63:225-231. (Pubitemid 34407082)
8. Karasu TB, Gelenberg A, Merriam A, Wang P (2000). American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder, second edition. Am J Psychiatry 157 (Suppl 4):1-45.
9. Katon W, Cantrell CR, Sokol MC, Chiao E, Gdovin JM (2005). Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 165:2497-2503. (Pubitemid 41720012)
10. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005a). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602. (Pubitemid 40973434)
11. Kessler RC, Chiu WT, Demler O, Walters EE (2005b). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627. (Pubitemid 40973437)
12. Liu XC, Chen Y, Faries D, Blackham J, Watson P (2009a). Adherence and persistence to branded and generic antidepressants in the usual treatment of patients with major depressive disorder. In: The 22nd Annual US Psychiatric and Mental Health Congress. Las Vegas, NV: US Psychiatric and Mental Health Congress.
13. Liu XC, Chen Y, Faries D, Miner C, Swindle R (2009b). Impact of comorbidities on antidepressant initiation: duloxetine, venlafaxine, and escitalopram versus other SSRIs. In: The 38th American College of Clinical Pharmacology Annual Meeting; 13-15 September. San Antonio, TX: American College of Clinical Pharmacology Annual Meeting.
14. Liu XC, Tepper P, Mullins CD (2010). Treatment persistence with duloxetine and health care costs in patients with major depressive disorder. In: The 15th Annual International Society for Pharmacoeconomics and Outcomes Research 15th Annual International Meeting; 15-19 May. Atlanta, GA: International Society for Pharmacoeconomics and Outcomes Research 15th Annual International Meeting.
15. Mandelberg JH, Kuhn RE, Kohn MA (2000). Epidemiologic analysis of an urban, public emergency department's frequent users. Acad Emerg Med 7:637-646. (Pubitemid 30390489)
16. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K (1998). The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55:1128-1132. (Pubitemid 28558286)
17. National Committee for Quality Assurance (2009). The healthcare effectiveness data and information set (HEDIS). Washington, DC: National Committee for Quality Assurance.
18. Nemeroff CB, Schatzberg AF, Goldstein DJ, Detke MJ, Mallinckrodt C, Lu Y, et al (2002). Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36:106-132.
19. Olfson M, Marcus SC, Tedeschi M, Wan GJ (2006). Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 163:101-108. (Pubitemid 43050110)
20. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007). A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10:3-12. (Pubitemid 46161090)
21. Qaseem A, Snow V, Denberg TD, Forciea MA, Owens DK (2008). Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:725-733.
22. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. (2005). Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43:1130-1139. (Pubitemid 41587600)
23. Ruhé HG, Huyser J, Swinkels JA, Schene AH (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67:1836-1855. (Pubitemid 46055194)
24. Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ (2008). Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 22:963-973.
25. Sood N, Treglia M, Obenchain RL, Dulisse B, Melfi CA, Croghan TW (2000). Determinants of antidepressant treatment outcome. Am J Manag Care 6:1327-1336. (Pubitemid 32043656)
26. Thompson D, Buesching D, Gregor KJ, Oster G (1996). Patterns of antidepressant use and their relation to costs of care. Am J Manag Care 2:1239-1246. (Pubitemid 126477345)
27. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G (2004). The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 61:1097-1103. (Pubitemid 39463410)
28. White TJ, Vanderplas A, Ory C, Dezli CM, Chang E (2003). Economic impact of patient adherence with antidepressant therapy within a managed care organization. Dis Manag Health Outcomes 11:817-822. (Pubitemid 38156313)
29. Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH (2009). Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs. J Med Econ 12:124-135.